
Novavax Inc
NVAX Real Time Price USDRecent trades of NVAX by members of U.S. Congress
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by NVAX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$170,000 Apr 28, 2025 Issue: Health Issues
-
$100,000 Jan 20, 2025 Issue: Health Issues
-
$90,000 Oct 18, 2024 Issue: Health Issues
-
$90,000 Jul 17, 2024 Issue: Health Issues
-
$130,000 Apr 19, 2024 Issue: Health Issues
-
$120,000 Jan 19, 2024 Issue: Health Issues
-
$120,000 Oct 20, 2023 Issue: Health Issues
-
$120,000 Jul 20, 2023 Issue: Health Issues
-
$150,000 Jan 20, 2023 Issue: Health Issues
-
$110,000 Oct 21, 2022 Issue: Health Issues
-
$110,000 Jul 20, 2022 Issue: Health Issues
-
$160,000 Apr 19, 2022 Issue: Health Issues
-
$150,000 Jan 17, 2022 Issue: HEALTH ISSUES
-
$120,000 Oct 19, 2021 Issue: HEALTH ISSUES
-
$110,000 Jul 20, 2021 Issue: HEALTH ISSUES
-
$100,000 Apr 20, 2021 Issue: HEALTH ISSUES
-
$60,000 Jan 18, 2021 Issue: HEALTH ISSUES
-
$90,000 Oct 20, 2020 Issue: None
-
$50,000 Jul 22, 2020 Issue: None
-
$10,000 May 11, 2020 Issue: TAXATION/INTERNAL REVENUE CODE
-
$10,000 Jan 03, 2020 Issue: TAXATION/INTERNAL REVENUE CODE
-
$10,000 Oct 18, 2019 Issue: Taxation/Internal Revenue Code
-
$10,000 Jul 18, 2019 Issue: Health Issues Taxation/Internal Revenue Code
-
$10,000 Apr 17, 2019 Issue: Taxation/Internal Revenue Code Budget/Appropriations
-
$10,000 Jan 18, 2019 Issue: Health Issues Taxation/Internal Revenue Code
-
$10,000 Oct 10, 2018 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code
-
$20,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Health Issues Budget/Appropriations
-
$20,000 Apr 18, 2018 Issue: Taxation/Internal Revenue Code Budget/Appropriations
-
$20,000 Jan 19, 2018 Issue: Taxation/Internal Revenue Code Health Issues
-
$30,000 Oct 20, 2017 Issue: Taxation/Internal Revenue Code
-
$30,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Budget/Appropriations
-
$10,000 Apr 20, 2017 Issue: Health Issues Budget/Appropriations
-
$20,000 Jan 20, 2017 Issue: Medicare/Medicaid Health Issues Budget/Appropriations
-
$50,000 Oct 18, 2016 Issue: Medicare/Medicaid Health Issues Budget/Appropriations
-
$10,000 Jul 25, 2016 Issue: Health Issues
-
$10,000 Jul 20, 2016 Issue: Health Issues
-
$30,000 Apr 20, 2016 Issue: Health Issues
-
$10,000 Jan 20, 2016 Issue: Health Issues
-
$10,000 Oct 20, 2015 Issue: Health Issues
-
$10,000 Jul 20, 2015 Issue: Health Issues
-
$10,000 Apr 20, 2015 Issue: Health Issues
-
$10,000 Jan 14, 2015 Issue: Health Issues
-
$15,000 Oct 17, 2014 Issue: Health Issues
-
$10,000 Sep 04, 2014 Issue: Health Issues
-
$20,000 Apr 18, 2014 Issue: Health Issues
-
$15,000 Jan 15, 2014 Issue: Health Issues
-
$10,000 Oct 14, 2013 Issue: Health Issues
-
$7,000 Jul 16, 2013 Issue: Health Issues
-
$30,000 Jul 19, 2011 Issue: Health Issues
-
$30,000 Apr 18, 2011 Issue: Health Issues
-
$30,000 Jan 19, 2011 Issue: Health Issues
-
$30,000 Oct 19, 2010 Issue: Health Issues
-
$30,000 Jul 17, 2010 Issue: Health Issues
-
$30,000 Apr 18, 2010 Issue: Health Issues
-
$30,000 Jan 20, 2010 Issue: Health Issues
-
$30,000 Oct 20, 2009 Issue: Health Issues
-
$30,000 Jul 20, 2009 Issue: Health Issues
-
$20,000 Apr 20, 2009 Issue: Financial Institutions/Investments/Securities
-
$20,000 Aug 09, 2006 Issue: Budget/Appropriations
-
$20,000 Feb 13, 2006 Issue: Budget/Appropriations
-
$20,000 Mar 26, 2002 Issue: Defense Budget/Appropriations Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
NVAX Revenue by Segment or Geography
New patents grants
-
Patent Title: Methods and compositions for inducing immune responses against Mar. 26, 2024
-
Patent Title: Corona virus vaccine formulations Feb. 13, 2024
-
Patent Title: Multivalent influenza nanoparticle vaccines Feb. 13, 2024
-
Patent Title: Coronavirus vaccine formulations Jan. 03, 2023
-
Patent Title: Modified rsv f proteins and methods of their use Sep. 20, 2022
-
Patent Title: Vaccine compositions having improved stability and immunogenicity Jun. 21, 2022
-
Patent Title: Multivalent influenza nanoparticle vaccines Mar. 22, 2022
-
Patent Title: Coronavirus vaccine formulations Feb. 22, 2022
-
Patent Title: Vaccine compositions having improved stability and immunogenicity Feb. 22, 2022
-
Patent Title: Methods and compositions for inducing immune responses against clostridium difficile Sep. 21, 2021
-
Patent Title: Modified rsv f proteins and methods of their use Jul. 06, 2021
-
Patent Title: Coronavirus vaccine formulations Mar. 23, 2021
-
Patent Title: Composition comprising iscom particles and live micro-organisms Oct. 27, 2020
-
Patent Title: Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods Aug. 25, 2020
-
Patent Title: Influenza vaccine Aug. 11, 2020
-
Patent Title: Iscom preparation and use thereof Aug. 04, 2020
-
Patent Title: Functional influenza virus like particles (vlps) Aug. 04, 2020
-
Patent Title: Functional influenza virus-like particles (vlps) Feb. 04, 2020
-
Patent Title: Highly efficient influenza matrix (m1) proteins Jan. 28, 2020
-
Patent Title: Influenza vaccine Nov. 26, 2019
-
Patent Title: Vaccine compositions having improved stability and immunogenicity Oct. 01, 2019
-
Patent Title: Functional influenza virus like particles (vlps) Jan. 29, 2019
-
Patent Title: Rabies glycoprotein virus-like particles (vlps) Oct. 02, 2018
-
Patent Title: Modified rsv f proteins and methods of their use Jul. 17, 2018
-
Patent Title: Functional influenza virus-like particles (vlps) May. 01, 2018
-
Patent Title: Highly efficient influenza matrix (m1) proteins Apr. 24, 2018
-
Patent Title: Functional influenza virus-like particles (vlps) Apr. 10, 2018
-
Patent Title: Compositions comprising iscom particles and live micro-organisms Feb. 27, 2018
-
Patent Title: Modified rsv f proteins and methods of their use Aug. 15, 2017
-
Patent Title: Rabies glycoprotein virus-like particles (vlps) Aug. 08, 2017
-
Patent Title: Modified rsv f proteins and methods of their use Aug. 01, 2017
-
Patent Title: Functional influenza virus like particles (vlps) Jul. 04, 2017
-
Patent Title: Modified rsv f proteins and methods of their use Jun. 13, 2017
-
Patent Title: Functional influenza virus-like particles (vlps) Apr. 18, 2017
-
Patent Title: Functional influenza virus-like particles (vlps) Oct. 25, 2016
-
Patent Title: Highly efficient influenza matrix (m1) proteins Oct. 11, 2016
-
Patent Title: Vlps derived from cells that do not express a viral matrix or core protein Jul. 05, 2016
-
Patent Title: Composition comprising iscom particles and live micro-organisms Dec. 08, 2015
-
Patent Title: Functional influenza virus-like particles (vlps) Nov. 10, 2015
-
Patent Title: Functional influenza virus-like particles (vlps) Sep. 29, 2015
-
Patent Title: Functional influenza virus like particles (vlps) Jun. 09, 2015
-
Patent Title: Highly efficient influenza matrix (m1) proteins Mar. 31, 2015
-
Patent Title: Functional influenza virus-like particles (vlps) Feb. 10, 2015
-
Patent Title: Quil a fraction with low toxicity and use thereof Sep. 02, 2014
-
Patent Title: Modified rsv f proteins and methods of their use May. 06, 2014
-
Patent Title: Vlps derived from cells that do not express a viral matrix or core protein Apr. 15, 2014
-
Patent Title: Functional influenza virus-like particles (vlps) Nov. 26, 2013
-
Patent Title: Avian influenza chimeric vlps Oct. 08, 2013
-
Patent Title: Functional influenza virus like particles (vlps) Aug. 13, 2013
-
Patent Title: Functional influenza virus like particles (vlps) Dec. 20, 2011
Federal grants, loans, and purchases
- $7,250 2024-05-30 00:00:00 Agency: Department of Health and Human Services
- $7,250 2024-05-30 00:00:00 Agency: Department of Health and Human Services
- $0 2023-07-12 00:00:00 Agency: Department of Veterans Affairs
- $7,250 2023-06-14 00:00:00 Agency: Department of Health and Human Services
- $7,250 2023-06-14 00:00:00 Agency: Department of Health and Human Services
- $0 2022-12-28 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded from public contracts
Recent insights relating to NVAX
Recent picks made for NVAX stock on CNBC
ETFs with the largest estimated holdings in NVAX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
---|
- Is $NVAX stock a Buy, Sell, or Hold?
- What is the price target for $NVAX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
Shareholder
|
Shares Held
|
---|
- Who owns $NVAX stock?
- Who owns the most shares of $NVAX stock?
- What funds own $NVAX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVAX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.